Novartis has submitted its meningococcal B vaccine Bexsero to the EU for marketing approval. "The Bexsero submission in the EU is an important milestone toward achieving the world's first broad-coverage MenB vaccine through our unique multi-component approach," said Andrin Oswald, head of Novartis Vaccines and Diagnostics Division. "Meningococcal disease is sudden and aggressive, leaving little time for treatment. Proactive vaccination of individuals has been shown to offer the best protection against fatal infectious diseases. Novartis is committed to providing vaccines to protect people of all ages, including infants, and against all causes, of meningococcal disease." Novartis release